School of Chemistry, University of Bristol, Bristol, BS8 1TS, UK.
Department of Life Sciences, University of Bath, Bath, BA2 7AY, UK.
J R Soc Med. 2023 Feb;116(2):65-75. doi: 10.1177/01410768221133566. Epub 2022 Nov 16.
In 2019-2020, four national recommendations were published in the United Kingdom to encourage use of low carbon inhalers. This study aimed to investigate whether these were associated with a change in primary care dispensing in England and to explore associations between geographical variation and clinical commissioning group (CCG) characteristics.
Ecological study using aggregated publicly available data.
All CCGs in England (March 2016 to February 2021).
not applicable.
Percentage of low carbon inhalers dispensed.
The percentage of low carbon inhalers dispensed was 26.3% in 2020-2021 (of 8.8 million inhalers). This decreased over the study period for short-acting beta-agonist (SABA), inhaled corticosteroid (ICS) and ICS+long-acting beta-agonist (LABA) inhalers. The same trend was seen for LABA and ICS+LABA+long-acting muscarinic antagonist inhalers from 2019. The SABA and ICS classes were less often dispensed as low carbon inhalers (⁓6% versus 35-45%). Interrupted time series analyses found slight increases in low carbon inhaler percentage in the SABA, LABA and ICS classes after April 2019, which were soon erased by the long-term trend. There was also geographical variation, with the north-west, Birmingham and London consistently dispensing more low carbon inhalers. The presence of advice on climate change in CCG formularies/guidelines, the prevalence of asthma and population age profile were associated with significant variation in low carbon inhaler percentage for some classes.
The percentage of low carbon inhalers dispensed in England remains low and continues to decrease. Greater use of low carbon inhalers is achievable, but is more likely with locally implemented initiatives.
2019-2020 年,英国发布了四项国家建议,以鼓励使用低碳吸入器。本研究旨在调查这些建议是否与英格兰初级保健配药的变化有关,并探讨地理差异与临床委托组(CCG)特征之间的关联。
使用聚合的公开可用数据进行的生态研究。
英格兰所有 CCG(2016 年 3 月至 2021 年 2 月)。
不适用。
低碳吸入器的配药比例。
2020-2021 年(880 万支吸入器)低碳吸入器的配药比例为 26.3%。在研究期间,短效β-激动剂(SABA)、吸入皮质类固醇(ICS)和 ICS+长效β-激动剂(LABA)吸入器的比例下降。2019 年也出现了 LABA 和 ICS+LABA+长效毒蕈碱拮抗剂吸入器的相同趋势。SABA 和 ICS 类别的低碳吸入器配药比例较低(⁓6%对 35-45%)。中断时间序列分析发现,2019 年 4 月后,SABA、LABA 和 ICS 类别的低碳吸入器比例略有增加,但很快被长期趋势所抹去。此外,还存在地理差异,西北部、伯明翰和伦敦一直使用更多的低碳吸入器。CCG 处方/指南中关于气候变化的建议、哮喘的流行率和人口年龄分布与某些类别的低碳吸入器比例的显著差异有关。
英格兰低碳吸入器的配药比例仍然较低,且持续下降。更广泛地使用低碳吸入器是可行的,但更有可能通过地方实施的倡议来实现。